Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
International Journal of Molecular Sciences · 12.03.2024 · 25 (6) · 3234
DOI: 10.3390/ijms25063234 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.03.2024. Verfasst von Samir Mouhssine und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della …. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Ministero della Salute, University of Eastern Piedmont Amadeo Avogadro.
Abstract (Originalsprache)
The B cell receptor (BCR) signaling pathway plays a crucial role in B cell development and contributes to the pathogenesis of B cell neoplasms. In B cell malignancies, the BCR is constitutively active through both ligand-dependent and ligand-independent mechanisms, resulting in continuous Bruton tyrosine kinase (BTK) signaling activation, which provides a survival and proliferation advantage to the neoplastic clone. Among B cell malignancies, those in which the most significant results were obtained by treatment with BTK inhibitors (BTKi) include chronic lymphocytic leukemia, mantle cell lymphoma, lymphoplasmacytic lymphoma, and diffuse large B cell lymphoma. Covalent BTKi (namely ibrutinib, acalabrutinib, and zanubrutinib) functions by irreversibly blocking BTK through covalent binding to the cysteine residue 481 (Cys-481) in the ATP-binding domain. Despite the high efficacy and safety of BTKi treatment, a significant fraction of patients affected by B cell malignancies who are treated with these drugs experience disease relapse. Several mechanisms of resistance to covalent BTKi, including Cys-481 mutations of BTK, have been investigated in B cell malignancies. Non-covalent BTKi, such as pirtobrutinib, have been developed and proven effective in patients carrying both Cys-481-mutated and unmutated BTK. Moreover, targeting BTK with proteolysis-targeting chimeras (PROTACs) represents a promising strategy to overcome resistance to BTKi in B cell neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.
- Department of Hematology and Bone Marrow Transplant, Hematology and Bone Marrow Transplant Center, Medical City, Baghdad 00964, Iraq.
- Department of Clinical Hematology, The National Center of Hematology, Mustansiriyah University, Baghdad 10015, Iraq.
ORCID-Profile: Samir Mouhssine, Nawar Maher, Bassam Francis Matti, Gianluca Gaidano
Förderung
- Italian Association for Cancer Research
- Ministero della Salute
- University of Eastern Piedmont Amadeo Avogadro
- Associazione Italiana Contro le Leucemie Linfomi e Mieloma
- Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy
- Italian MoH, Rome, Italy
- Next Generation EU
- AGING Project—Department of Excellence—DIMET, Università del Piemonte Orientale, Novara, Italy
Zitieren
APA
Mouhssine, S., Maher, N., Matti, B. F., Alwan, A. F., & Gaidano, G. (2024). Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms. International Journal of Molecular Sciences, 25(6), 3234. https://doi.org/10.3390/ijms25063234
Vancouver
Mouhssine S, Maher N, Matti BF, Alwan AF, Gaidano G. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms. International Journal of Molecular Sciences. 2024;25(6):3234. doi:10.3390/ijms25063234
BibTeX
@article{Mouhssine2024,
author = {Mouhssine, Samir and Maher, Nawar and Matti, Bassam Francis and Alwan, Alaa Fadhil and Gaidano, Gianluca},
title = {Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3234},
doi = {10.3390/ijms25063234}
}
EUVIMED